Overview

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shandong Luye Pharmaceutical Co., Ltd.
Treatments:
Huperzine A